Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brachyspira yeast plus bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2400079593Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of saccharomyces boulardii in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Helicobacter pylori eradication rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400079593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079593.